Common Key Genes in Differentiating Parathyroid Adenoma From Thyroid Adenoma

Abstract

Recent studies have demonstrated the close relationship between parathyroid adenoma (PA) and thyroid follicular adenoma (FTA). However, the underlying pathogenesis remains unknown. This study focused on exploring common pathogenic genes, as well as the pathogenesis of these two diseases, through bioinformatics methods. This work obtained PA and FTA datasets from the Integrated Gene Expression Database to identify the common differentially expressed genes (DEGs) of two diseases. The functions of the genes were investigated by GO and KEGG enrichment. The program CytoHubba was used to select the hub genes, while receiver operating characteristic curves were plotted to evaluate the predictive significance of the hub genes. The DGIbd database was used to identify gene-targeted drugs. This work detected a total of 77 DEGs. Enrichment analysis demonstrated that DEGs had activities of 3′,5′-cyclic AMP, and nucleotide phosphodiesterases and were associated with cell proliferation. NOS1, VWF, TGFBR2, CAV1, and MAPK1 were identified as hub genes after verification. The area under the curve of PA and FTA was>0.7, and the hub genes participated in the Relaxin Signaling Pathway, focal adhesion, and other pathways. The construction of the mRNA-miRNA interaction network yielded 11 important miRNAs, while gene-targeting drug prediction identified four targeted drugs with possible effects. This bioinformatics study demonstrated that cell proliferation and tumor suppression and the hub genes co-occurring in PA and FTA, have important effects on the occurrence and progression of two diseases, which make them potential diagnostic biomarkers and therapeutic targets.

Key words

parathyroid adenoma - thyroid adenoma -  thyroid - key genes - bioinformatics - drug prediction

Publikationsverlauf

Eingereicht: 23. Oktober 2022

Angenommen nach Revision: 15. Dezember 2022

Accepted Manuscript online:
04. Januar 2023

Artikel online veröffentlicht:
27. Februar 2023

• References

• 1 Shi YH, Dixit J, Koh D. et al. Functional and genetic studies of isolated cells from parathyroid tumors reveal the complex pathogenesis of parathyroid neoplasia. Proc Natl Acad Sci U S A 2014; 111: 3092-3097
• 2 Ishii H, Mihai R, Watkinson JC. et al. Systematic review of cure and recurrence rates following minimally invasive parathyroidectomy. BJS Open 2018; 2: 364-370
• 3 Sala TD, Muresan S, Roman R. et al. Hypercalcaemic crisis due to primary hyperparathyroidism: report of two cases. J Crit Care Med (Targu Mures) 2019; 5: 34-39
• 4 Theurer SSU, Lorenz K, Dralle H. et al. Ektopes Gewebe der Schilddrüse und der Nebenschilddrüsen Ectopic tissue of the thyroid gland and the parathyroid glands. Pathologe 2018; 39: 379-389
• 5 Rodrigo JP, Hernandez-Prera JC, Randolph GW. et al. Parathyroid cancer: an update. Cancer Treat Rev 2020; 86: 102012
• 6 Verdelli C, Morotti A, Tavanti GS. et al. The core stem genes SOX2, POU5F1/OCT4, and NANOG are expressed in human parathyroid tumors and modulated by MEN1, YAP1, and beta-catenin pathways activation. Biomedicines 2021; 9: 637
• 7 Papanikolaou A, Katsamakas M, Boudina M, Pamporaki C. et al. Intrathyroidal parathyroid adenoma mimicking thyroid cancer. Endocrine Journal 2020; 67: 639-643
• 8 Saljo K, Thornell A, Jin C. et al. Characterization of glycosphingolipids in the human parathyroid and thyroid glands. Int J Mol Sci 2021; 22: 7044
• 9 Erickson LA, Mete O, Juhlin CC. et al. Overview of the 2022 WHO classification of parathyroid tumors. Endocr Pathol 2022; 33: 64-89
• 10 Michael P, Bannon MD, Van Heerden MB. et al. The relationship between primary hyperparathyroidism and diabetes mellitus. Ann Surg 1988; 207: 430-433
• 11 Paloyan Walker RKE, Gopalsami C, Bassali J. et al. Hyperparathyroidism associated with a chronic hypothyroid state. Laryngoscope 1997; 107: 903-909
• 12 Yavropoulou MP, Poulios C, Michalopoulos N. et al. A role for circular non-coding RNAs in the pathogenesis of sporadic parathyroid adenomas and the impact of gender-specific epigenetic regulation. Cells 2018; 8: 15
• 13 Verdelli C, Forno I, Vaira V. et al. Epigenetic alterations in human parathyroid tumors. Endocrine 2015; 49: 324-332
• 14 Vaira V, Elli F, Forno I. et al. The microRNA cluster C19MC is deregulated in parathyroid tumours. J Mol Endocrinol 2012; 49: 115-124
• 15 Hu Y, Zhang X, Cui M. et al. Circular RNA profile of parathyroid neoplasms: analysis of co-expression networks of circular RNAs and mRNAs. RNA Biol 2019; 16: 1228-1236
• 16 Li Q, Li Y, Sun X. et al. Genomic analysis of abnormal DNAM methylation in parathyroid tumors. Int J Endocrinol 2022; 4995196
• 17 The Gene Ontology C The gene ontology resource: 20 years and still GOing strong. Nucleic Acids Res 2019; 47: D330-D338
• 18 Kanehisa M, Furumichi M, Sato Y. et al. KEGG: integrating viruses and cellular organisms. Nucleic Acids Res 2021; 49: D545-D551
• 19 Szklarczyk D, Gable AL, Lyon D. et al. STRING v11: protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets. Nucleic Acids Res 2019; 47: D607-D613
• 20 Otasek D, Morris JH, Boucas J. et al. Cytoscape automation: empowering workflow-based network analysis. Genome Biol 2019; 20: 185
• 21 Zhou G, Soufan O, Ewald J. et al. NetworkAnalyst 3.0: a visual analytics platform for comprehensive gene expression profiling and meta-analysis. Nucleic Acids Res 2019; 47: W234-W241
• 22 Freshour SL, Kiwala S, Cotto KC. et al. Integration of the drug-gene interaction database (DGIdb 4.0) with open crowdsource efforts. Nucleic Acids Res 2021; 49: D1144-D1151
• 23 Fukumura D, Kashiwagi S, Jain RK. The role of nitric oxide in tumour progression. Nat Rev Cancer 2006; 6: 521-534
• 24 Li X, Zou Z, Tang J. et al. NOS1 upregulates ABCG2 expression contributing to DDP chemoresistance in ovarian cancer cells. Oncol Lett 2019; 17: 1595-1602
• 25 Wang Q, Ye S, Chen X. et al. Mitochondrial NOS1 suppresses apoptosis in colon cancer cells through increasing SIRT3 activity. Biochem Biophys Res Commun 2019; 515: 517-523
• 26 Brait M, Loyo M, Rosenbaum E. et al. Correlation between BRAF mutation and promoter methylation of TIMP3, RARbeta2 and RASSF1A in thyroid cancer. Epigenetics 2012; 7: 710-719
• 27 Kong QFLB, Wang B, Zhang XP. et al. Association of von Willebrand factor (vWF) expression with lymph node metastasis and hemodynamics in papillary thyroid carcinoma. Eur Rev Med Pharmacol Sci 2020; 24: 2564-2571
• 28 Mishra SMV, Kumar S. Ankita et al. Clinical management and therapeutic strategies for the thyroid-associated ophthalmopathy: current and future perspectives. Curr Eye Res 2020; 45: 1325-1341
• 29 Peres KC, Teodoro L, Amaral LHP. et al. Clinical utility of TGFB1 and its receptors (TGFBR1 and TGFBR2) in thyroid nodules: evaluation based on single nucleotide polymorphisms and mRNA analysis. Arch Endocrinol Metab 2021; 65: 172-184
• 30 Kardalas E, Sakkas E, Ruchala M. et al. The role of transforming growth factor beta in thyroid autoimmunity: current knowledge and future perspectives. Rev Endocr Metab Disord 2022; 23: 47
• 31 Imam N, Alam A, Siddiqui MF. et al. Identification of key regulators in parathyroid adenoma using an integrative gene network analysis. Bioinformation 2020; 16: 910-922
• 32 Shankar J, Wiseman SM, Meng F. et al. Coordinated expression of galectin-3 and caveolin-1 in thyroid cancer. J Pathol 2012; 228: 56-66
• 33 Chai YJ, Chae H, Kim K. et al. Comparative gene expression profiles in parathyroid adenoma and normal parathyroid tissue. J Clin Med 2019; 8: 297
• 34 Nie FR, Li QX, Wei HF. et al. miR-326 inhibits the progression of papillary thyroid carcinoma by targeting MAPK1 and ERBB4. Neoplasma 2020; 67: 604-613
• 35 Chen H, Li Q, Yi R. et al. CircRNA casein kinase 1 gamma 1 (circ-CSNK1G1) plays carcinogenic effects in thyroid cancer by acting as miR-149-5p sponge and relieving the suppression of miR-149-5p on mitogen-activated protein kinase 1 (MAPK1). J Clin Lab Anal 2022; 36: e24188
• 36 Blake JF, Burkard M, Chan J. et al. Discovery of (S)-1-(1-(4-Chloro-3-fluorophenyl)-2-hydroxyethyl)-4-(2-((1-methyl-1H-pyrazol-5-y l)amino)pyrimidin-4-yl)pyridin-2(1H)-one (GDC-0994), an extracellular signal-regulated kinase 1/2 (ERK1/2) inhibitor in early clinical development. J Med Chem 2016; 59: 5650-5660
• 37 Zhu J, Wang J, Wang X. et al. Prediction of drug efficacy from transcriptional profiles with deep learning. Nat Biotechnol 2021; 39: 1444-1452
• 38 Janardhan HP, Dresser K, Hutchinson L. et al. Pathological MAPK activation-mediated lymphatic basement membrane disruption causes lymphangiectasia that is treatable with ravoxertinib. JCI Insight 2022; 7: e153033